Spruce Biosciences Inc (NAS:SPRB)

$ 0.4054 0.0099 (2.5%) Market Cap: 16.34 Mil Enterprise Value: -40.49 Mil PE Ratio: 0 PB Ratio: 0.32 GF Score: 32/100

Spruce Biosciences Inc at Jefferies Healthcare Conference Transcript
Jun 09, 2023
Spruce Biosciences Inc at RBC Capital Markets Global Healthcare Conference Transcript
May 17, 2023
Spruce Biosciences Inc at JMP Securities Life Sciences Conference Transcript
May 15, 2023
Spruce Biosciences Inc at SVB Securities Global Biopharma Conference (Virtual) Transcript
Feb 15, 2023
Spruce Biosciences Inc at Jefferies London Healthcare Conference Transcript
Nov 15, 2022
Spruce Biosciences Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Sep 12, 2022
Spruce Biosciences Inc at JMP Securities Life Sciences Conference Transcript
Jun 16, 2022
Spruce Biosciences Inc at RBC Capital Markets Global Healthcare Conference Transcript
May 17, 2022

Spruce Biosciences Inc at Jefferies Healthcare Conference Transcript

Jun 09, 2023 / 01:30PM GMT

Release Date Price: $2.31 (-0.86%)

Transcript

Unidentified Participant

Javier Szwarcberg, CEO of Bruce Biosciences.

Javier Szwarcberg

Spruce Biosciences, Inc. - CEO

Thank you, Russell, and thank you, Jefferies, for having me and Spruce here. A real pleasure to be sharing our company and our data.

So, I guess I have a clicker. So, I'll be making some forward-looking statements along my presentation. I'll refer you to prior SEC filings and prior press releases and other sources of communications that we've issued in the past.

So let me tell you a little bit about Spruce. So, we're a rare disease endocrinology company. We're developing tildacerfont for the treatment of CAH and PCOS. And pretty excited to be moving our programs forward. We believe the CAH market is a fairly large commercial opportunity of approximately $3 billion. There is significant unmet need. There has been no innovation in the CAH field for over 50, 60 years, mainly since the advent of synthetic steroids.

We in-licensed tildacerfont from Eli Lilly in 2016. tildacerfont is a second-generation CRF-1 receptor antagonist.

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.